Paragon 28, Inc. (FNA) Q4 2023 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
While the company reported strong revenue growth and expects positive EBITDA in 2024, the decline in gross profit margins and ongoing EBITDA losses are concerning. The Q&A revealed optimism about future growth and product launches, but management's vagueness on some strategies and the significant EBITDA loss temper enthusiasm. The lack of market cap data prevents a precise prediction, but the mixed signals suggest a neutral stock price movement.
Key Financial Performance
Global Revenue Q4 2023 $60.6 million, representing 17.6% reported growth and 17.3% constant currency growth compared to Q4 2022.
U.S. Revenue Q4 2023 $51.7 million, representing 14.1% growth over the prior year quarter.
International Revenue Q4 2023 $8.9 million, representing 43.1% reported growth and 40.7% constant currency growth year-over-year.
Gross Profit Margin Q4 2023 74.5%, compared to 81.5% in Q4 2022, impacted by $4 million in non-cash inventory write-downs.
Gross Profit Margin Full Year 2023 79.9%, compared to 82.1% for the full year 2022, with inventory write-downs affecting margins.
Adjusted EBITDA Q4 2023 $4.4 million loss, compared to a $1.5 million loss in Q4 2022, including the $4 million inventory write-down.
Adjusted EBITDA Full Year 2023 $9.7 million loss, an improvement of $1 million compared to the prior year period.
Operating Cash Use 2022 and 2023 Approximately $113 million, compared to approximately break-even operating cash flow in both 2020 and 2021.
Total Liquidity Approximately $125 million, consisting of $75 million cash and $50 million available through credit facility.
Operating Highlights
New Product Launches: In Q4 2023, Paragon 28 launched two new solutions: the JAWS Great White Nitinol Staple System and the BEAST Cortical Fiber Bone Graft. In early 2024, five additional product launches were announced, including the Grappler Knotless Anchor and the FJ2000 Power Console.
Market Expansion: Paragon 28 has established a direct or directly managed commercial model in 13 of its 22 international markets, indicating a strong international presence and growth potential.
Operational Efficiency: The company increased its U.S. sales roster by 14% and surgeon customer base by 9%, indicating improved operational efficiency and growth potential.
Supply Chain Improvement: The supply chain environment has improved significantly compared to previous quarters, contributing to better operational performance.
Strategic Shifts: Paragon 28 is transitioning into a more scalable organization, focusing on enhancing infrastructure and processes to support future growth.
Risk or Challenges
Supply Chain Challenges: Supply chain headwinds continued into the fourth quarter, although they were less significant than in previous quarters. The company noted an improving supply chain environment.
Inventory Write-downs: The company recorded non-cash inventory write-downs totaling $4 million during the fourth quarter, which negatively impacted gross profit margins.
Operating Cash Use: The company experienced approximately $113 million in operating cash use for 2022 and 2023 combined, compared to break-even cash flow in 2020 and 2021.
Legal Settlement: A non-recurring legal settlement contributed to the operating cash use during 2022 and 2023.
Macroeconomic Environment: The company acknowledged that its revenue guidance is balanced with respect to uncontrollable factors, including the macroeconomic environment.
Competitive Pressures: The company expects the foot-and-ankle market to continue outpacing broader orthopedic market growth, which may indicate competitive pressures.
Guidance & Outlook
Global Revenue 2023: Global revenue for the full year 2023 was $216.4 million, representing 19.3% reported growth and 19.7% constant currency growth.
U.S. Sales Roster Growth: Increased U.S. producing sales roster by almost 14%, reaching 266 reps compared to Q4 2022.
Surgeon Customer Base Growth: Grew surgeon customer base by 9% to a record 2,215 surgeons.
Product Launches 2024: Five meaningful product launches and one limited market release announced already in Q1 2024.
Innovation Focus: Launched two new solutions in Q4 2023 and expect significant impact from early 2024 product launches.
Smart28 Platform: First reveal of the Smart28 platform expected mid-year 2024.
2024 Revenue Guidance: For the full year of 2024, estimated net revenue to be between $249 million and $259 million, representing a range of 15% to 20% growth.
Q1 2024 Growth Comparison: First quarter of 2024 is expected to be the toughest growth comparison of the year due to prior year performance.
Quarterly Growth Expectations: Anticipate quarterly growth rates for the rest of the year to be higher than in Q1 2024.
Gross Profit Margin Outlook: Expect annual gross profit margins to continue to be approximately 80% going forward.
Adjusted EBITDA Expectations: Committed to driving positive adjusted EBITDA on an annual basis beginning in 2024.
Shareholder Return Plan
Share Repurchase Program: The company has approximately $125 million of total liquidity, consisting of $75 million of cash on the balance sheet and $50 million available through its credit facility, which may be utilized for future share repurchase initiatives.
Key Q&A
Earnings Word Cloud
FNA Transcript
The earnings call reveals strong financial performance, with record revenue growth, improved EBITDA, and free cash flow. The company has increased revenue guidance and expects further cost savings from restructuring. While gross margin decreased slightly, it is expected to stabilize. The Q&A section indicates optimism about future growth and cost savings. Despite some management ambiguity, the overall sentiment is positive, supported by strong earnings, optimistic guidance, and a positive market reaction to new product launches. This suggests a likely stock price increase of 2% to 8% over the next two weeks.
The earnings call reveals mixed signals: strong revenue growth (19.6% YoY) and positive international performance, but declining gross margins and cash flow challenges. The operational efficiency plan and narrowed revenue guidance reflect caution amidst economic uncertainties. The Q&A section highlights management's focus on long-term EBITDA and cash flow positivity, but lacks specifics. Despite positive product development, the cautious guidance and macroeconomic concerns suggest a neutral stock price movement over the next two weeks.
While the company reported strong revenue growth and expects positive EBITDA in 2024, the decline in gross profit margins and ongoing EBITDA losses are concerning. The Q&A revealed optimism about future growth and product launches, but management's vagueness on some strategies and the significant EBITDA loss temper enthusiasm. The lack of market cap data prevents a precise prediction, but the mixed signals suggest a neutral stock price movement.
FNA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
